These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Synthesis of the C12-C19 fragment of (+)-peloruside A through a diastereomer-discriminating RCM reaction. Roulland E; Ermolenko MS Org Lett; 2005 May; 7(11):2225-8. PubMed ID: 15901175 [TBL] [Abstract][Full Text] [Related]
8. Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane human NK1 antagonists. Swain CJ; Seward EM; Cascieri MA; Fong TM; Herbert R; MacIntyre DE; Merchant KJ; Owen SN; Owens AP; Sabin V J Med Chem; 1995 Nov; 38(24):4793-805. PubMed ID: 7490729 [TBL] [Abstract][Full Text] [Related]
9. Three-component domino process for the pyrrolizine skeleton via [3 + 2]-cycloaddition-enamine cyclization triggered by a gold catalyst. Sugimoto K; Yamamoto N; Tominaga D; Matsuya Y Org Lett; 2015 Mar; 17(5):1320-3. PubMed ID: 25700009 [TBL] [Abstract][Full Text] [Related]
10. Formation of bicyclic pyrroles from the catalytic coupling reaction of 2,5-disubstituted pyrroles with terminal alkynes, involving the activation of multiple C-H bonds. Yi CS; Zhang J Chem Commun (Camb); 2008 May; (20):2349-51. PubMed ID: 18473066 [TBL] [Abstract][Full Text] [Related]
11. Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides. Filla SA; Mathes BM; Johnson KW; Phebus LA; Cohen ML; Nelson DL; Zgombick JM; Erickson JA; Schenck KW; Wainscott DB; Branchek TA; Schaus JM J Med Chem; 2003 Jul; 46(14):3060-71. PubMed ID: 12825944 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: estrogen antagonists of unusual structure. Zhou HB; Comninos JS; Stossi F; Katzenellenbogen BS; Katzenellenbogen JA J Med Chem; 2005 Nov; 48(23):7261-74. PubMed ID: 16279785 [TBL] [Abstract][Full Text] [Related]
16. Total synthesis of epohelmin B and its analogues. Fürstner A; Korte A Chem Asian J; 2008 Feb; 3(2):310-8. PubMed ID: 18061922 [TBL] [Abstract][Full Text] [Related]
17. Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). Devasthale P; Wang Y; Wang W; Fevig J; Feng J; Wang A; Harrity T; Egan D; Morgan N; Cap M; Fura A; Klei HE; Kish K; Weigelt C; Sun L; Levesque P; Moulin F; Li YX; Zahler R; Kirby MS; Hamann LG J Med Chem; 2013 Sep; 56(18):7343-57. PubMed ID: 23964740 [TBL] [Abstract][Full Text] [Related]
18. Stereoselective synthesis of a dioxa-bicyclo[3.2.1]octane SGLT2 inhibitor. Mascitti V; Préville C Org Lett; 2010 Jul; 12(13):2940-3. PubMed ID: 20527898 [TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists. Hanessian S; Babonneau V; Boyer N; Mannoury la Cour C; Millan MJ; De Nanteuil G Bioorg Med Chem Lett; 2014 Jan; 24(2):510-4. PubMed ID: 24374277 [TBL] [Abstract][Full Text] [Related]